This study compares the effects of Packed Red Blood Cells (PRBCs) prepared in two different ways on the transfusion indices in beta(ß)-Thalassemia transfusion-dependent patients. The two blood components types derive from the whole blood. In one case, the whole blood is leukoreduced with subsequent plasma removal. In the other case, plasma, buffy coat, and red blood cells (RBCs) are first separated and subsequently, the RBCs leukoreduced. Each type of blood components will be subsequently given to one-half of the patients for a 6-month period and to the other half for other 6-month at the randomization phase, for a total of 12 months of crossed-treatment per patient.
At Day Hospital Talassemia ed Emoglobinopatie of Ferrara, two different PRBCs are available. The two types of blood components are obtained from whole blood, pre-storage leukoreduced and suspended in saline-adenine-glucose-mannitol (SAGM). One method of preparation consists of the whole blood leukoreduction with subsequent plasma removal. The other method first separates plasma, buffy coat, and RBCs, and then the RBCs are leukoreduced. The two methods mainly differ in the final haemoglobin (Hb) content: the Hb level is lower (-13%, approximately) in the second method that also shows the advantage to produce platelets from the buffy coat. A PRBCs unit is not as strictly defined as a therapeutic medication dose (pill or vial): individual PRBCs units may substantially differ in their Hb content, much more than the average difference between the two types of preparations. The aim of this study is to document the extent of the average difference between the two types of preparations, and its impacts on the transfusion indices of ß-Thalassaemia transfusion-dependent patients. All patients will receive each blood component for a period of 6 months (crossover design), for a total of 12 months of transfusion treatment per patient.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
Day Hospital Thalassaemia and Haemoglobinopathies (DHTE)
Ferrara, Italy
Transfusion Power Index
(Average pre-transfusion Hb concentration)/(Unit Index) \[for the definition of Unit Index, see the secondary outcomes\]
Time frame: For each of the two blood components studied, at the end of 6-month period of study
Average pre-transfusion Hb concentration
Mean pre-transfusion Hb levels, calculated starting from the second transfusion of the period to the first transfusion of the following period
Time frame: For each of the two blood components studied, at the end of 6-month period of study
Unit Index
(Total number of PRBCs (A or B) transfused in the period)/(Number of days between the first transfusion of the period and the first transfusion of the following period)
Time frame: For each of the two blood components studied, at the end of 6-month period of study
Average Transfusion Interval
(Number of days between the first transfusion of the period and the first transfusion of the following period)/(Number of transfusions in the period)
Time frame: For each of the two blood components studied, at the end of 6-month period of study
Number of Transfusion Reactions
Number of transfusion reactions to the two blood components that may occur in the study periods (2 periods of 6 months each)
Time frame: Study periods (2 periods of 6 months each)
Transfusion Reaction Rate
(Number of transfusion reactions to the two blood components occurring in the study periods)/(Total number of PRBCs (A or B) transfused in the period)
Time frame: Study periods (2 periods of 6 months each)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.